WE SUSTAIN ADDED VALUES

Vitruvia Medical AG

Financial statement half-year as per Juni 30th, 2024

Incl. Management report as per June 30th, 2024

Alle Zahlen in CHF

Bilanz per 30. Juni 2024

	30.06.24 CHF	30.06.23 CHF
AKTIVEN		
Umlaufvermögen		
Flüssige Mittel	1'866.56	132'962.50
Forderungen ggn. Tochtergesellschaften	0.00	0.00
Sonstige Forderungen	1'946.45	12'055.25
Aktive Rechnungsabgrenzungen	0.00	0.00
	3'813.01	**145'017.75**
Anlagevermögen		
langfristige Finanzanlagen	245'562.50	187'625.00
Beteiligungen	1'607'819.00	1'607'819.00
	1'853'381.50	**1'795'444.00**
TOTAL AKTIVEN	**1'857'194.51**	**1'940'461.75**
PASSIVEN		
Kurzfristiges Fremdkapital		
Verbindlichkeiten aus Lieferungen und Leistungen	1'638.36	63'044.10
Verbindlichkeiten ggn. Nahestehende	20'000.00	0.00
kurzfristige Finanzverbindlichkeiten	1.82	0.00
Passive Rechnungsabgrenzungen	41'620.00	37'150.00
	63'260.18	**100'194.10**
Langristiges Fremdkapital		
Wandelanleihe - 2% 2022 - 2025	1'155'000.00	1'055'000.00
	1'155'000.00	**1'055'000.00**
Eigenkapital		
Aktienkapital	2'511'578.00	2'511'578.00
Reserven aus Kapitaleinlagen	10'979'786.25	10'979'786.25
Verlustvortrag	-12'799'041.86	-12'555'145.76
Jahresverlust	-53'388.06	-150'950.84
	638'934.33	**785'267.65**
TOTAL PASSIVEN	**1'857'194.51**	**1'940'461.75**

Erfolgsrechnung
1. Januar 2024 bis 30. Juni 2024
Vorjahr 1. Januar 2023 bis 30. Juni 2023

	2024 CHF	2023 CHF
Verwaltungsaufwand		
Verwaltungsaufwand	0.00	0.00
Rechts- und Beratungsaufwand	5'727.15	18'527.55
Organisationskosten	16'539.66	45'942.61
Büro- und Verwaltungskosten	8'073.72	14'061.31
	30'340.53	**78'531.47**
Finanzertrag		
Zinserträge	0.01	0.00
Darlehenszinsen (aktiv)	0.00	0.00
	0.01	**0.00**
Finanzaufwand		
Bankzinsen und -spesen/Depotgebühren	866.20	57.00
Darlehenszinsen (passiv)	34'700.00	60'265.33
Kursdifferenzen	-12'938.66	11'610.44
	22'627.54	**71'932.77**
Ergebnis Finanzrechnung	**-22'627.53**	**-71'932.77**
Wertberichtigungen Darlehen/Beteiligungen	0.00	0.00
Periodenfremder Ertrag	0.00	0.00
Ergebnis vor Steuern	**-52'968.06**	**-150'464.24**
Steuern	420.00	486.60
Ergebnis nach Steuern	**-53'388.06**	**-150'950.84**

WE SUSTAIN ADDED VALUES

Management report as of June 30, 2024

Vitruvia Medical AG achieved results as expected in the first half of 2024. The Board of Directors confirms the forecast for the year as a whole.

Vitruvia Medical AG is on target in the first six months of 2024. The result amounted to CHF -52,968.06 compared to CHF -150,464.24 in the previous year. Based on the results for the first half of 2024, which were as expected, the company's management confirms the outlook for the current year as a whole. For this period, the Board of Directors expects consolidated sales of around EUR 2.0 million. On a consolidated basis, Vitruvia Medical AG anticipates a further improvement in earnings compared to the previous year.

Operating performance in the first half of 2024 and outlook

The cooperation with a German full-service provider was expanded in the first half of the year and will be extended in the second half of the year with additional major customers. A large hospital group will be added on 01.08.2024.

Closer cooperation with an Austrian company has resulted in significant revenue growth, which will be further expanded in the future.

LT technologies GmbH & Co. KG is currently in negotiations with a major manufacturer in the medical technology sector to take a further step towards OEM repair services in the third quarter.

As a major competitor in Germany is closing down at the end of the year. LT technologies GmbH & Co. KG is well on the way to taking 3rd place in Germany in the repair service sector. Interest in working with LT technologies GmbH & Co. KG, as there are hardly any alternatives that offer the quality and range of services in this form.

Due to the rethinking of customers in the area of sustainability, LT technologies GmbH & Co. KG is on the right track and equipped for the future. The special effect of sustainability is that the hospitals are relieved of their expenses, their efficiency is maintained and they do something good for the environment.

In addition to the pleasing development of the LT technologies GmbH & Co. KG investment, Vitruvia Medical AG continues to keep an eye out for interesting acquisition opportunities in order to expand its portfolio.

Anglikon, July 26, 2024

Vitruvia Medical AG
Board of Directors